

**CLAIMS**

This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Currently Amended) A method of blocking an immune response to an allogeneic foreign graft in a mammal, where the mammal is not suffering from a malignancy, comprising administering to the mammal a therapeutically effective amount of an antibody which binds to CD20.
- 2-4. (Cancelled)
5. (Original) The method of claim 1 wherein the mammal is human.
6. (Previously Presented) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.
7. (Previously Presented) The method of claim 1 wherein the antibody comprises rituximab.
8. (Previously Presented) The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.
9. (Original) The method of claim 8 wherein the cytotoxic agent is a radioactive compound.
10. (Previously Presented) The method of claim 9 wherein the antibody comprises Y2B8 or <sup>131</sup>I-B1.
11. (Previously Presented) The method of claim 1 comprising administering the antibody intravenously.

12. (Previously Presented) The method of claim 1 comprising administering the antibody subcutaneously.
13. (Currently Amended) The method of claim 1, comprising administering a dose of from about 20mg/m<sup>2</sup> to about 1000 less than 375 mg/m<sup>2</sup> of the antibody to the mammal.
14. (Original) The method of claim 13 wherein the dose is in the range from about 20mg/m<sup>2</sup> to about 250mg/m<sup>2</sup>.
15. (Original) The method of claim 14 wherein the dose is in the range from about 50mg/m<sup>2</sup> to about 200mg/m<sup>2</sup>.
16. (Previously Presented) The method of claim 1 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m<sup>2</sup> dose of the antibody in the subsequent dose exceeds the mg/m<sup>2</sup> dose of the antibody in the initial dose.
- 17-21. (Cancelled)
22. (Previously Presented) The method of claim 1 comprising administering the antibody to the mammal before the mammal is exposed to the graft.
- 23-27. (Cancelled)
28. (Currently Amended) A method of treating graft-versus-host or host-versus-graft disease in a mammal human, wherein the graft is from a human having the same or a different genetic origin as the human being treated, comprising administering to the mammal human a therapeutically effective amount of an antibody which binds to CD20.

29-31. (Cancelled)

32. (Newly Added) The method of claim 10, wherein the antibody comprises Y2B8.
33. (Newly Added) The method of claim 10, wherein the antibody comprises  $^{131}\text{I}$ -B1.
34. (Newly Added) The method of claim 1, wherein the antibody is a human antibody.
35. (Newly Added) The method of claim 1, wherein the antibody is a chimeric antibody.
36. (Newly Added) The method of claim 1, wherein the antibody is a humanized antibody.
37. (Newly Added) The method of claim 28, wherein the antibody is a human antibody.
38. (Newly Added) The method of claim 28, wherein the antibody is a chimeric antibody.
39. (Newly Added) The method of claim 28, wherein the antibody is a humanized antibody.
40. (Newly Added) The method of claim 28, wherein the antibody comprises rituximab.
41. (Newly Added) The method of claim 28, wherein the antibody comprises Y2B8.
42. (Newly Added) The method of claim 28, wherein the antibody comprises  $^{131}\text{I}$ -B1.